Macfarlane 1986.

Study characteristics
Methods	Design: parallel Duration: 12 weeks Assessment: baseline and post‐intervention Country: Canada
Participants	Pain condition: RA Population: adults with RA and elevated self‐reported depression Minimum pain intensity: no Inclusion criteria ‘Definite’ or ‘classical’ RA as defined by the ARA All of the patients had a score exceeding 50 on the ‘self‐rating depression scale’ described by Zung 1965 Exclusion criteria: NR Total participants randomised: 36 Age in years (mean, SD): 59.15 Gender: 27/36 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 18 Inert Identical tablets Trimipramine 75 mg n = 18 TCA Fixed titration schedule to 75 mg, but if participants experienced side effects they could reduce the dose
Outcomes	Pain intensity Mood Withdrawal
Missing data methods	NR
Funding source	NR
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedure not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical study drugs
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information on handling missing data, report 9 participants withdrew in the text but 10 in the table Attrition Total: 9/36 (25.0%) Placebo: 4/18 (22.2%) Trimipramine 25‐75 mg: 5/18 (27.8%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Unclear risk	Not a lot of information on methods, short publication so not enough information to assess whether a further risk of bias exists